Last updated: December 3, 2024
Sponsor: Michael C Willey
Overall Status: Active - Recruiting
Phase
2/3
Condition
N/ATreatment
Ropivacaine, Epinephrine, Ketorolac, NaCL
Ropivacaine, Epinephrine, Ketorolac, NaCl (Saline)
Clinical Study ID
NCT06519955
202311233
Ages 13-50 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Adolescent or young adult diagnosed with hip dysplasia indicated for PAO atUniversity of Iowa Hospital and Clinics.
Exclusion
Exclusion Criteria:
Unable to provide informed consent.
Pregnant or breast-feeding individuals
Prisoner or ward of the state
Allergy or medical contradiction to any of the study medications
Patients undergoing femoral osteotomy or surgical hip dislocation with PAO will beexcluded
Study Design
Total Participants: 120
Treatment Group(s): 2
Primary Treatment: Ropivacaine, Epinephrine, Ketorolac, NaCL
Phase: 2/3
Study Start date:
October 03, 2024
Estimated Completion Date:
September 30, 2026
Study Description
Connect with a study center
University of Iowa Health Care
Iowa City, Iowa 52242
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.